No Evidence that CD33 rs12459419 Polymorphism Predicts Gemtuzumab Ozogamicin Response in Consolidation Treatment of Acute Myeloid Leukemia Patients: Experience of the PETHEMA Group

  1. Castaño-Bonilla, T.
  2. Barragán, E.
  3. Sargas, C.
  4. Sanz, A.
  5. Algarra, L.
  6. Herrera-Puente, P.
  7. García-Boyero, R.
  8. Barrios, M.
  9. Martinez-Cuadron, D.
  10. Rodriguez-Veiga, R.
  11. Boluda, B.
  12. Gil, C.
  13. Serrano-López, J.
  14. Martínez-López, J.
  15. Sayas-Lloris, M.J.
  16. Olave, M.T.
  17. Riaza-Grau, R.
  18. Castillo, T.B.-D.
  19. Larrayoz, M.J.
  20. Amigo, R.
  21. Jiménez-Velasco, A.
  22. Sánchez, J.
  23. Ayala, R.
  24. Blas, C.
  25. Lainez, D.
  26. Serrano-López, J.
  27. Sanz, M.A.
  28. Alonso-Domínguez, J.M.
  29. Montesinos, P.
  30. Show all authors +
Journal:
Disease markers

ISSN: 1875-8630

Year of publication: 2022

Volume: 2022

Pages: 3132941

Type: Article

DOI: 10.1155/2022/3132941 GOOGLE SCHOLAR lock_openOpen access editor

Sustainable development goals

Data source: Scopus